Results 181 to 190 of about 50,998 (262)

Effects of the HDAC6/8 Inhibitor MC1568, Alone and in Combination With Fluconazole, in Non‐Albicans Candida Species Infections

open access: yesMicrobiologyOpen, Volume 15, Issue 4, August 2026.
This study explores new antifungal strategies to combat non‐albicans Candida species. We tested clinically approved HDAC inhibitors—Vorinostat, Romidepsin, Tucidinostat—and the HDAC6/8‐selective MC1568, alone and with Fluconazole. The Fluconazole/MC1568 combination significantly enhanced antifungal activity and reduced biofilm formation.
Andrea Giammarino   +10 more
wiley   +1 more source

Systemic and ocular complications related to intravitreal administration of anti-VEGF agents. [PDF]

open access: yesMed Hypothesis Discov Innov Ophthalmol
Koksaldi S   +3 more
europepmc   +1 more source

Reprogramming Glial Cell Metabolism via a tRNA Fragment Preserves Vision in Retinal Neurodegeneration

open access: yesMedComm, Volume 7, Issue 8, August 2026.
Under oxidative and excitotoxic stress, Müller cell‐derived 5′tiRNA‐His‐GTG contributes to retinal neurodegeneration. Pathological stimuli increase ANG‐dependent production of 5′tiRNA‐His‐GTG, which suppresses LPCAT1 expression and disrupts phosphatidylcholine (PC)‐mediated glycerophospholipid metabolism.
Yuke Ji   +9 more
wiley   +1 more source

Targeting Melanoma‐Specific Tyrosinase Disrupts Cytoskeleton Dynamics for Precision Apoptosis Induction by a De Novo Designed Cyclic Peptide

open access: yesMedComm, Volume 7, Issue 8, August 2026.
This study develops a tyrosinase‐activated cyclic peptide self‐assembly system to combat drug‐resistant melanoma. Cyclization of tyrosine/lysine‐rich peptides via ortho‐phthalaldehyde enables tyrosinase‐triggered quinone formation and nanostructure assembly, disrupting melanoma cell cytoskeletons by blocking actin polymerization and inducing apoptosis.
Ruoyang Zhao   +13 more
wiley   +1 more source

Advancing Treatment of Degenerative Eye Diseases at the Nanoscale

open access: yesSmart Medicine, Volume 5, Issue 4, August 2026.
Nanotherapeutics possess the potential to overcome longstanding bottlenecks in treating degenerative ophthalmic diseases. With a highly tunable surface chemistry, nanotechnology platforms can be customized to navigate specific anatomical barriers in the eye and target pathways of diseases.
Li Yao Jin   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy